Prosecution Insights
Last updated: November 04, 2026

Dyve Biosciences Inc.

Technology area: Biotechnology & Pharmaceuticals

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready

Analysis

Dyve Biosciences Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 5 distinct examiners and 5 distinct art units. BABSON, NICOLE PLOURDE is the busiest examiner, with 1 pending matter.

The pending work is distributed across five examination channels. This structure may produce different treatments of biological, pharmaceutical, formulation, or therapeutic limitations. Counsel should therefore use application-specific prosecution analysis while keeping shared scientific terminology and disclosure positions consistent.

No examiner is shown as handling more than the stated 1 pending matter. A coordinated review can organize common technical evidence and identify recurring claim issues, but each response should remain tied to the cited references and reasoning in its own action.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
2
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (40%)
3
Medium (60%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (40%)
Double-patenting + other1 (20%)
Multi-statute (no §101)2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BABSON, NICOLE PLOURDE 1 46.5% +33.9%
SONG, JIANFENG 1 56.4% +32.8%
MOU, LIYUAN 1 43.8% +59.9%
KETCHAM, KAREN A 1 21.1% +39.9%
BARBER, KIMBERLY 1 71.1% +21.4%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18796818 FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS BABSON, NICOLE PLOURDE —
17817774 TOPICAL DELIVERY OF BUFFERING AGENTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS KETCHAM, KAREN A —

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17830236 TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS BARBER, KIMBERLY 73d overdue
18351192 TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS MOU, LIYUAN 49d overdue
18796818 FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS BABSON, NICOLE PLOURDE —
18782470 TRANSDERMAL CARRIER SONG, JIANFENG —
17817774 TOPICAL DELIVERY OF BUFFERING AGENTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS KETCHAM, KAREN A —

Top Art Units

Art UnitApps
1619 1
1613 1
1628 1
1614 1
1615 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18796818 FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS BABSON, NICOLE PLOURDE 1619 §102§103§112Other Non-Final OA — Pending Aug 07, 2024
18782470 TRANSDERMAL CARRIER SONG, JIANFENG 1613 §103Other Non-Final OA — Pending Jul 24, 2024
18351192 TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS MOU, LIYUAN 1628 §102§103§112DP Final Rejection 49d overdue Pending Jul 12, 2023
17817774 TOPICAL DELIVERY OF BUFFERING AGENTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS KETCHAM, KAREN A 1614 §102§103§112 Final Rejection — Pending Aug 05, 2022
17830236 TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS BARBER, KIMBERLY 1615 §103 Final Rejection 73d overdue Pending Jun 01, 2022

Managing Dyve Biosciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Dyve Biosciences Inc. have?

Dyve Biosciences Inc. has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.

Which USPTO examiner handles the most Dyve Biosciences Inc. applications?

Nicole Plourde Babson has the most, with 1 of Dyve Biosciences Inc.'s pending office actions.

What technology area are Dyve Biosciences Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month